Big Pharma has some serious ground to cover when it comes to global sales and marketing. Worldwide spending for prescription branded drugs and generic medicines is set to increase 30% from 2013-2018, a yearly growth rate of more than 5%, with $1.3 trillion in annual global drug sales on the line, according to data from the Institute of Healthcare Informatics cited by The Motley Fool blog. And drugmakers should look past traditional markets for their cut of the profits.
Big Pharma's ads for branded meds generally try to impart inspirational messages and are meant to educate patients about a particular brand, helping them feel more connected to a company or product. But consumers aren't feeling the love, according to a new study from patient advocacy network Wego Health Solutions.
Which Big Pharma companies have the biggest market caps in the industry? The Motley Fool has a breakdown of the top 10, but we'll give you a hint: The list begins with Johnson & Johnson and Novartis.
The big question of the day is whether the unprecedented bull market we've been seeing generate billions of dollars for biotech is sustainable or has transformed into a fragile bubble ready to pop. And we decided to put that question to our audience of subscribers, looking for a revealing snapshot of what the industry is thinking today.
Nimbus Therapeutics is ready to see how the compounds it discovered with the help of Schrödinger's computational chemistry tools fare in the clinic. And the VC units of Eli Lilly, GlaxoSmithKline and Pfizer want to find out, too, prompting each to chip in to Nimbus' $43 million Series B round.
Ten companies count on one top product to supply a major chunk of their sales, the business news site Quartz calculates. And several of those are either anticipating some serious pain from a near-term patent expiration or already suffering from competition.
Big Pharma's image among patient groups got a boost last year, but biotech is still winning the popularity contest.
Big Pharma has been hiring out all sorts of functions companies once did in-house: sales, manufacturing, and IT services, to name a few. But according to The Wall Street Journal, one of the fastest-growing fields for pharma contractors isn't any of these. It's drug safety.
When it comes to currency, it's not been a good couple of weeks for multinational drugmakers. Switzerland's move to decouple the franc from the euro last week raised questions about the effects on Basel-based Roche and Novartis. And now, Johnson & Johnson's fourth-quarter results and 2015 forecast are triggering more foreign exchange worries.
After 2014's growth spurt, Pfizer's vaccines unit is not done expanding. The pharma giant has grabbed privately held Swiss company Redvax for an undisclosed sum, adding a preclinical human cytomegalovirus (CMV) vaccine candidate and a tech platform and IP related to a second, undisclosed vaccine program.